✦ LIBER ✦

Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients

✍ Scribed by David W. Ollila; Mark C. Kelley; Guy Gammon; Donald L. Morton

Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 96 KB
Volume: 14
Category: Article
ISSN: 8756-0437
DOI: 10.1002/(sici)1098-2388(199806)14:4<328::aid-ssu9>3.0.co;2-4

No coin nor oath required. For personal study only.

✦ Synopsis

Although a phase III trial has yet to show a statistically significant improvement in the disease-free or overall survival of melanoma patients receiving vaccine therapy, several phase II trials have shown enhanced disease-free and overall survival of patients who develop a humoral and/or cellular response to a melanoma vaccine. The challenge of active specific immunotherapy research is to determine which combination of humoral and cellular immune responses optimizes clinical outcome and how to monitor the immune response effectively. This review identifies key components of a successful melanoma vaccine, discusses new ways to modulate and stimulate the immune system, and summarizes some of the important clinical trials of active specific immunotherapy for patients with melanoma.

📜 SIMILAR VOLUMES

Update on active specific immunotherapy

Update on active specific immunotherapy with melanoma vaccines

✍ Conforti, Arnold M.; Ollila, David W.; Kelley, Mark C.; Gammon, Guy; Morton, Don 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

Although a randomized clinical trial has yet to show a statistically significant improvement in the survival of patients receiving vaccine therapy for malignant melanoma, several studies have shown enhanced survival of patients developing an immune response to a melanoma vaccine. The knowledge and t

Active specific immunotherapy with polyv

Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases

✍ Eddy C. Hsueh; Larry Nathanson; Leland J. Foshag; Richard Essner; J. Anne Nizze; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB 👁 1 views

## BACKGROUND. This study was conducted to document the rate, duration, and type of objective response to active specific immunotherapy with a polyvalent melanoma cell vaccine (PMCV) for patients with in-transit melanoma metastases and to identify any acute or chronic toxic effects of PMCV treatme

Adjuvant immunotherapy for patients with

Adjuvant immunotherapy for patients with melanoma: Are patients with melanoma of the head and neck candidates for this therapy?

✍ Palma M. Shaw; Muthukumaran Sivanandham; Stephanie F. Bernik; Kristen Ditaranto; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 1 views

Background. Although a wealth of information is available on adjuvant immunotherapy for melanoma, little is known about adjuvant immunotherapy for head and neck melanoma. Interestingly, a few immunotherapy clinical trials report the observation of clinical responses in a subset of patients with head

In vivo activation of melanoma-specific

In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells

✍ Daniel E. Speiser; Danielle Liénard; Mikaël J. Pittet; Pascal Batard; Donata Rim 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB 👁 1 views

High homogeneity of MAGE, BAGE, GAGE, Ty

High homogeneity of MAGE, BAGE, GAGE, Tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: Implications for protocol design of therapeutic antigen-specific vaccination strategies

✍ Piero Dalerba; Axel Ricci; Vincenzo Russo; Donata Rigatti; Maria Rita Nicotra; M 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 58 KB 👁 1 views

Human melanoma cells express several antigens which are recognized by autologous and specific CTL clones in association with HLA-class-I molecules. Many of these antigens represent suitable targets for tumor immunotherapy, since their expression in human melanoma cells is common and highly specific.